secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001104659-24-062544
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q1 2024 net loss $5.0M; cash $16.4M, extended by $14M April raise
------------------------------------------------------------------------------

- Cash $16.4M at March 31, 2024; raised $14M in April from TPAV/OrbiMed, funding into Q4 2024.
- Net loss $5.0M ($0.24/shr) vs $5.8M ($0.28/shr) in Q1 2023; R&D down to $1.9M from $4.1M.
- Completed acquisition of Trawsfynydd and concurrent $14M private placement in April 2024.
- Initiated Phase 1 dosing for COVID candidate ratutrelvir; last dose cohort for narazaciclib done.
- Plans Phase 2 for influenza and COVID in H2 2024; topline data expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/0001104659-24-062544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924062544/tm2414653d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer